[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] Rapid acting insulin and pump

Rapid-Acting Insulin Compatible With Pump-Delivered Continuous Insulin 
Infusion Therapy WESTPORT, CT (Reuters Health) Jan 16 - Results of a new 
study indicate the rapid-acting insulin analog, insulin aspart, is safe and 
effective for continuous subcutaneous insulin infusion (CSII) therapy. Dr. 
Bruce W. Bode of Atlanta Diabetes Associates in Georgia, and Dr. Poul Strange 
of Novo Nordisk Pharmaceuticals in Princeton, New Jersey, report their study 
results in the January issue of Diabetes Care. In a single-center randomized 
open-label study, 19 patients received CSII with insulin aspart, while 10 
received CSII with buffered regular human insulin. Bolus doses of insulin 
aspart were given immediately prior to meals, and bolus doses of human 
insulin 30 minutes before meals. The study lasted for 7 weeks. Insulin aspart 
and buffered regular human insulin performed equally well in controlling 
daily blood glucose levels and maintaining glycosylate hemoglobin levels. 
"Insulin aspart appears to have less hypoglycemia than regular insulin in 
pump patients and is definitely more convenient," Dr. Bode told Reuters 
Health. He pointed out that, currently, buffered regular insulin is the only 
approved insulin for pumps. "Insulin aspart is a fast-acting insulin analogue 
that is comparable to Lilly's lispro (humalog). The benefit is that it is 
compatible and efficacious in pumps and will probably get FDA approval," Dr. 
Bode added. Diabetes Care 2001;24:69-72.    
 <A HREF="http://transplantation.medscape.com/reuters/prof/2001/01/01.17/20010116clin002.html">Rapid-Acting Insulin Compatible With Pump-Delivered Continuous Insulin 
Infusion Therapy</A> 
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml